ZEUS Trial Finds Anti-Inflammatory Drug Misses Heart Goal
Ziltivekimab lowered inflammation markers but did not reduce heart attacks, strokes or cardiovascular deaths versus placebo in a global phase 3 trial.
Updated on Nov. 9, 2026 in Heart Disease

The ZEUS phase 3 trial, led by Paul Ridker of Mass General Brigham and sponsored by Novo Nordisk, tested ziltivekimab, a drug targeting interleukin-6 (IL-6). The drug lowered IL-6 levels but showed no statistically significant reduction in cardiovascular events compared with placebo.
Why it matters
The results challenge the hypothesis that blocking inflammation alone can prevent heart events, a question raised by earlier anti-inflammatory research. Researchers say the findings point to the need for better-targeted trials in specific patient groups.
The trial recorded 561 primary endpoint events in the ziltivekimab group versus 565 in the placebo group, a difference that was not statistically significant. Researchers have not yet determined whether differences in the trial population, which was a decade older than in the earlier CANTOS trial, account for the outcome.
The players
Paul Ridker
Paul Ridker is a cardiologist at Mass General Brigham who led the ZEUS trial and has long studied inflammation as a driver of heart disease.
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company best known for diabetes and obesity drugs, and it sponsored the ZEUS trial of ziltivekimab.
The details
ZEUS enrolled people with atherosclerotic cardiovascular disease and systemic inflammation, many with significant kidney disease and longstanding diabetes or heart failure. Safety data showed no effect on total mortality, though a small increase in infection rates was observed.
Timeline
November 8, 2026: ZEUS findings presented at the American Heart Association Scientific Session and published in the New England Journal of Medicine.
Health Landscape
The ZEUS result follows the CANTOS trial, which showed fewer heart events with an IL-1beta inhibitor and prompted wider interest in inflammation as a cardiovascular target. The divergent outcome suggests that the benefit of anti-inflammatory therapy may depend heavily on which patients are treated and when.
For people with heart disease, the trial means ziltivekimab is not yet an established way to lower heart attack or stroke risk. Patients should continue discussing proven risk-reduction strategies with their own clinicians.
The takeaway
Lowering an inflammation marker does not automatically prevent heart events, so treatment effects appear to depend on the patient group. Further trials will need to identify who benefits from anti-inflammatory therapy and at what stage of disease.
Further reading
Explore more on Heart Disease for context on how inflammation and cardiovascular risk are being studied.
More information
Read the full NEJM ZEUS trial publication on ziltivekimab in the New England Journal of Medicine.







